Skip to main content
SpringerLink
Log in

Supplementation with DHEA in Poor Responder Patients

  • Chapter
Book cover Frontiers in Gynecological Endocrinology

Part of the book series: ISGE Series ((ISGE))

  • 1151 Accesses

Abstract

Poor response to ovarian stimulation (POR) usually indicates a reduction in follicular response to ovarian stimulation during in vitro fertilization (IVF) cycles resulting in a reduced number of retrieved oocytes. In recent years, mainly due to the postponement of childbearing and the consequent decrease of ovarian reserve, often a POR occurs during IVF despite the high dose of gonadotropins administered. Incidence of POR has been reported from 9 to 24 % [1, 2], and even if this condition may occur unexpectedly, its prevalence increases with age, and it is >50 % in patients over 40 years [3]. Patients with POR are defined as poor responders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 64.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC (2009) How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 91:749–766

    Article  CAS  PubMed  Google Scholar 

  2. Fasouliotis SJ, Simon A, Laufer N (2000) Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet 17:357–373

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L (2011) ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 26:1616–1624

    Article  CAS  PubMed  Google Scholar 

  4. Loverro G, Nappi L, Mei L, Giacomoantonio L, Carriero C, Tartagni M (2003) Evaluation of functional ovarian reserve in 60 patients. Reprod Biomed Online 7:200–204

    Article  CAS  PubMed  Google Scholar 

  5. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR (1996) Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 81:1038–1045

    CAS  PubMed  Google Scholar 

  6. Bancsi LF, Huijs AM, den Ouden CT, Broekmans FJ, Looman CW, Blankenstein MA et al (2000) Basal follicle-stimulating hormone levels are of limited value in predicting ongoing pregnancy rates after in vitro fertilization. Fertil Steril 73:552–557

    Article  CAS  PubMed  Google Scholar 

  7. Bancsi LFJMM, Broekmans FJM, Eijkemans MJC, de Jong FH, Habbema JDF, te Velde ER (2002) Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 77:328–336

    Article  PubMed  Google Scholar 

  8. Broekmans FJM, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F (2010) The antral follicle count: practical recommendations for better standardization. Fertil Steril 94:1044–1051

    Article  PubMed  Google Scholar 

  9. La Marca A, Spada E, Sighinolfi G, Argento C, Tirelli A, Giulini S et al (2011) Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 95:684–688

    Article  PubMed  Google Scholar 

  10. Durlinger ALL, Visser JA, Themmen APN (2002) Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction 124:601–609

    Article  CAS  PubMed  Google Scholar 

  11. Weenen C, Laven JSE, Von Bergh ARM, Cranfield M, Groome NP, Visser JA et al (2004) Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10:77–83

    Article  CAS  PubMed  Google Scholar 

  12. Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE (1999) Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 84:3836–3844

    PubMed  Google Scholar 

  13. Guibourdenche J, Lucidarme N, Chevenne D, Rigal O, Nicolas M, Luton D et al (2003) Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Mol Cell Endocrinol 211:55–63

    Article  CAS  PubMed  Google Scholar 

  14. La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, Giannella L et al (2005) Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 12:545–548

    Article  PubMed  Google Scholar 

  15. De Vet A, Laven JSE, de Jong FH, Themmen APN, Fauser BCJM (2002) Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77:357–362

    Article  PubMed  Google Scholar 

  16. Van Rooij IAJ, Broekmans FJM, te Velde ER, Fauser BCJM, Bancsi LFJMM, de Jong FH et al (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17:3065–3071

    Article  PubMed  Google Scholar 

  17. Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J (2003) Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18:323–327

    Article  CAS  PubMed  Google Scholar 

  18. Van Rooij IAJ, den Tonkelaar I, Broekmans FJM, Looman CWN, Scheffer GJ, de Jong FH et al (2004) Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11:601–606

    Article  PubMed  Google Scholar 

  19. Van Rooij IAJ, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, de Jong FH et al (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83:979–987

    Article  PubMed  Google Scholar 

  20. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P (2004) Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82:1323–1329

    Article  CAS  PubMed  Google Scholar 

  21. Fanchin R, Méndez Lozano DH, Louafi N, Achour-Frydman N, Frydman R, Taieb J (2005) Dynamics of serum anti-Müllerian hormone levels during the luteal phase of controlled ovarian hyperstimulation. Hum Reprod 20:747–751

    Article  CAS  PubMed  Google Scholar 

  22. Satwik R, Kochhar M, Gupta SM, Majumdar A (2012) Anti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilization. J Hum Reprod Sci 5:206–212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC et al (2010) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16:113–130

    Article  PubMed  Google Scholar 

  24. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM (2011) AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 17:46–54

    Article  CAS  PubMed  Google Scholar 

  25. Loutradis D, Vomvolaki E, Drakakis P (2008) Poor responder protocols for in-vitro fertilization: options and results. Curr Opin Obstet Gynecol 20:374–378

    Article  PubMed  Google Scholar 

  26. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S (2010) Interventions for “poor responders” to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev (1):CD004379

    Google Scholar 

  27. Burger HG (2002) Androgen production in women. Fertil Steril 77(Suppl 4):S3–S5

    Article  PubMed  Google Scholar 

  28. Walker ML, Anderson DC, Herndon JG, Walker LC (2009) Ovarian aging in squirrel monkeys (Saimiri sciureus). Reproduction 138:793–799

    Article  CAS  PubMed  Google Scholar 

  29. Casson PR, Carson SA, Buster JE (1998) Testosterone delivery systems for women: present status and future promise. Semin Reprod Endocrinol 16:153–159

    Article  CAS  PubMed  Google Scholar 

  30. Barad D, Gleicher N (2006) Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 21:2845–2849

    Article  CAS  PubMed  Google Scholar 

  31. Mamas L, Mamas E (2009) Premature ovarian failure and dehydroepiandrosterone. Fertil Steril 91:644–646

    Article  CAS  PubMed  Google Scholar 

  32. Hillier SG, Whitelaw PF, Smyth CD (1994) Follicular oestrogen synthesis: the “two-cell, two-gonadotrophin” model revisited. Mol Cell Endocrinol 100:51–54

    Article  CAS  PubMed  Google Scholar 

  33. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G et al (1998) Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 70:107–110

    Article  CAS  PubMed  Google Scholar 

  34. Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367

    CAS  PubMed  Google Scholar 

  35. Orvieto R, Bar-Hava I, Yoeli R, Ashkenazi J, Rabinerson D, Bar J et al (2004) Results of in vitro fertilization cycles in women aged 43–45 years. Gynecol Endocrinol 18:75–78

    Article  CAS  PubMed  Google Scholar 

  36. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA (1999) Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 61:353–357

    Article  CAS  PubMed  Google Scholar 

  37. Barad D, Brill H, Gleicher N (2007) Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 24:629–634

    Article  PubMed Central  PubMed  Google Scholar 

  38. Weil S, Vendola K, Zhou J, Bondy CA (1999) Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 84:2951–2956

    Article  CAS  PubMed  Google Scholar 

  39. Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N (2009) Role of androgens in the treatment of patients with low ovarian response. Reprod Biomed Online 19:888–898

    Article  CAS  PubMed  Google Scholar 

  40. Liu D, Iruthayanathan M, Homan LL, Wang Y, Yang L, Wang Y et al (2008) Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 149:889–898

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146:157–165

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  CAS  PubMed  Google Scholar 

  43. Lam PM, Haines C (2005) Vascular endothelial growth factor plays more than an angiogenic role in the female reproductive system. Fertil Steril 84:1775–1778

    Article  CAS  PubMed  Google Scholar 

  44. Van Blerkom J, Antczak M, Schrader R (1997) The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum Reprod 12:1047–1055

    Article  PubMed  Google Scholar 

  45. Barroso G, Barrionuevo M, Rao P, Graham L, Danforth D, Huey S et al (1999) Vascular endothelial growth factor, nitric oxide, and leptin follicular fluid levels correlate negatively with embryo quality in IVF patients. Fertil Steril 72:1024–1026

    Article  CAS  PubMed  Google Scholar 

  46. Battaglia C, Genazzani AD, Regnani G, Primavera MR, Petraglia F, Volpe A (2000) Perifollicular Doppler flow and follicular fluid vascular endothelial growth factor concentrations in poor responders. Fertil Steril 74:809–812

    Article  CAS  PubMed  Google Scholar 

  47. Kan A, Ng EHY, Yeung WSB, Ho PC (2006) Perifollicular vascularity in poor ovarian responders during IVF. Hum Reprod 21:1539–1544

    Article  CAS  PubMed  Google Scholar 

  48. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE (2000) Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 15:2129–2132

    Article  CAS  PubMed  Google Scholar 

  49. Gleicher N, Weghofer A, Barad D (2007) Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertil Steril 88, Supplement 1:S232

    Article  Google Scholar 

  50. Gleicher N, Weghofer A, Barad DH (2010) Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 8:140

    Article  PubMed Central  PubMed  Google Scholar 

  51. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH (2009) Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 7:108

    Article  PubMed Central  PubMed  Google Scholar 

  52. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A (2010) Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 25:2496–2500

    Article  CAS  PubMed  Google Scholar 

  53. Artini PG, Simi G, Ruggiero M, Pinelli S, Di Berardino OM, Papini F et al (2012) DHEA supplementation improves follicular microenvironment in poor responder patients. Gynecol Endocrinol 28:669–673

    Article  PubMed  Google Scholar 

  54. Chui DK, Pugh ND, Walker SM, Gregory L, Shaw RW (1997) Follicular vascularity–the predictive value of transvaginal power Doppler ultrasonography in an in-vitro fertilization programme: a preliminary study. Hum Reprod 12:191–196

    Article  CAS  PubMed  Google Scholar 

  55. Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L (2013) DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol 29:940–943

    Article  CAS  PubMed  Google Scholar 

  56. Mamas L, Mamas E (2009) Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol 21:306–308

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Paolo Giovanni Artini, Giovanna Simi, Maria Elena Rosa Obino, Sara Pinelli, Olga Maria Di Berardino, Francesca Papini, Maria Ruggiero & Vito Cela

Authors
  1. Paolo Giovanni Artini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanna Simi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Elena Rosa Obino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara Pinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olga Maria Di Berardino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesca Papini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Ruggiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vito Cela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Giovanni Artini .

Editor information

Editors and Affiliations

  1. Department of Reproductive Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

    Bart C. J. M. Fauser

  2. International Society of Gynecological Endocrinology, Pisa, Italy

    Andrea R. Genazzani

Rights and permissions

Reprints and permissions

Copyright information

© 2015 International Society of Gynecological Endocrinology

About this chapter

Cite this chapter

Artini, P.G. et al. (2015). Supplementation with DHEA in Poor Responder Patients. In: Fauser, B.C.J.M., Genazzani, A.R. (eds) Frontiers in Gynecological Endocrinology. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-09662-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09662-9_13

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09661-2

  • Online ISBN: 978-3-319-09662-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation